Reata Pharmaceuticals, Inc. (RETA)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ: RETA). The investigation concerns whether Reata and certain of its officers and/or directors have violated federal securities laws.


On August 10, 2020, Reata disclosed in its quarterly report for the second quarter of 2020 that the U.S. Food and Drug Administration (“FDA”) “is not convinced that the MOXIe Part 2 results” of the Company’s study assessing omaveloxolone for the treatment of Friedreich’s ataxia “will support a single study approval without additional evidence that lends persuasiveness to the results.  In preliminary comments for the meeting, the FDA stated that we will need to conduct a second pivotal trial that confirms the mFARS results of the MOXIe Part 2 study with a similar magnitude of effect.”  On this news, Reata’s stock price fell sharply during intraday trading on August 10, 2020.


If you are aware of any facts relating to this investigation, or purchased Reata shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.